Rohit Gosain, MD

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ breast cancer, particularly after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1m mutations at both the initial diagnosis of metastatic breast cancer (MBC) and at each subsequent progression using liquid biopsy assays.

Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- metastatic breast cancer, particularly in patients with ESR1 mutations.

Panelists give an overview of the LAURA trial, highlighting its objectives, methodologies, and key findings related to chronic spontaneous urticaria management.

Panelists provide an overview of the MARIPOSA trial, focusing on its aims, design, and significant results in the context of chronic spontaneous urticaria treatment.

Panelists provide an overview of the ADRIATIC study, highlighting its objectives, design, and significant results in the context of chronic spontaneous urticaria management.

Panelists give an overview of the MARIPOSA-2 trial, detailing its objectives, study design, and notable outcomes related to chronic spontaneous urticaria management.

Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.

Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing treatment options for anal cancer patients.

Panelists discuss how KEYNOTE-811's study design and key findings presented at the European Society for Medical Oncology (ESMO) Congress 2024 demonstrate the potential impact of pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric cancer treatment.

Panelists discuss how LEAP-012 trial results show promising progression-free survival, while anticipating further data on overall survival outcomes.

Panelists discuss how final thoughts emphasize the importance of ongoing research, collaborative care, and adapting treatment strategies to improve patient outcomes in the evolving therapy landscape.

Panelists discuss how surgical perspectives on durvalumab emphasize its role in enhancing patient outcomes, informing surgical decision-making, and integrating immunotherapy into comprehensive treatment plans.

Panelists discuss how considerations for treatment approach encompass patient-specific factors, treatment modalities, and the integration of emerging therapies to optimize outcomes in clinical practice.

Panelists discuss how the results and outcomes of the AEGEAN trial reveal significant findings regarding the treatment’s effectiveness and safety, shaping future approaches in patient care and management.

Panelists discuss how the importance of AEGEAN approval lies in its potential to enhance patient treatment options, paving the way for improved outcomes and informing clinical practice in the field.

Panelists discuss how the AEGEAN trial provides critical insights into the efficacy and safety of new therapeutic approaches, highlighting its design, key findings, and implications for future treatment strategies.

Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone metastases, providing crucial insights into treatment efficacy for these specific metastatic sites.

Panelists discuss how the EORTC-GUCG 1333 (PEACE-3) trial, presented at ESMO 2024, illuminates key findings regarding the study population and primary endpoints in genitourinary cancer research.

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ESMO 2024, shows potential for improving outcomes in certain cancer treatments.

Panelists discuss how overall survival and event-free survival data presented at ESMO 2024 demonstrate promising outcomes in cancer treatment.

Panelists discuss how ESMO 2024 presented important updates on primary end points and progression-free survival data from recent clinical studies.

Panelists discuss how updates from KEYNOTE-522 at ESMO 2024 revealed important data on overall survival and event-free survival outcomes.

Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory end points for evaluating a new cancer treatment.

Panelists discuss where and when sequencing axatilimab becomes appropriate within the clinical setting, as well as safety precautions associated with the drug.

Panelists discuss what the AGAVE-201 study displayed.

Panelists give an overview of chronic graft-vs-host disease, its history of treatment, how it is handled in the modern day, and the study design of AGAVE-201.

Panelists give an overview of Graft-vs-host Disease and the modern landscape of treatment.

Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on overall survival outcomes in patients with lung cancer, with a particular focus on survival rates across different histological subtypes.

Panelists discuss how the HARMONi-02 trial presented at World Conference on Lung Cancer 2024 revealed key lung cancer insights, focusing on progression-free survival and immune-related response criteria end points, while emphasizing the trial’s significance for specific patient subgroups.

Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.